
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
NanoViricides Inc (NNVC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NNVC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $6.5
1 Year Target Price $6.5
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.35% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.63M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 1 | Beta 0.96 | 52 Weeks Range 0.94 - 2.34 | Updated Date 08/15/2025 |
52 Weeks Range 0.94 - 2.34 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.38% | Return on Equity (TTM) -99.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18155948 | Price to Sales(TTM) - |
Enterprise Value 18155948 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.11 | Shares Outstanding 16072000 | Shares Floating 15504658 |
Shares Outstanding 16072000 | Shares Floating 15504658 | ||
Percent Insiders 3.53 | Percent Institutions 7.94 |
Upturn AI SWOT
NanoViricides Inc
Company Overview
History and Background
NanoViricides, Inc. was founded in 2003 and is headquartered in Shelton, Connecticut. The company focuses on developing antiviral therapies based on its proprietary nanoviricideu00ae technology.
Core Business Areas
- Nanoviricides Drug Development: The company develops nanoviricides, which are specifically designed antiviral drugs, for various viral diseases.
- Nanobiotherapeutic Platform Technology: NanoViricides owns its novel nanobiotherapeutic platform technology and is exploring additional fields of application in nanomedicines.
Leadership and Structure
Dr. Anil Diwan is the Executive Chairman, President, and CEO. The company operates with a focused management team and scientific advisory board guiding its research and development efforts.
Top Products and Market Share
Key Offerings
- Herpes Nanoviricides: The company is developing nanoviricides for herpes simplex virus (HSV-1 and HSV-2) infections. Market share data is unavailable as the product is still in preclinical and early clinical stages. Competitors: GlaxoSmithKline (GSK), Pfizer (PFE), Novartis (NVS).
- COVID-19 Nanoviricides: Development of nanoviricides for treating COVID-19. Market share data is unavailable as the product is still in preclinical and early clinical stages. Competitors: Pfizer (PFE), Merck (MRK), Gilead Sciences (GILD).
Market Dynamics
Industry Overview
The antiviral drug market is driven by the increasing prevalence of viral infections and the growing demand for effective treatments. The market is characterized by intense competition and regulatory scrutiny.
Positioning
NanoViricides is positioned as an innovative developer of novel antiviral therapies using its nanoviricide technology. Its competitive advantage lies in its targeted drug delivery system.
Total Addressable Market (TAM)
The global antiviral drugs market is expected to reach approximately $60 billion by 2028. NanoViricides aims to capture a share of this market through its innovative nanoviricide technology.
Upturn SWOT Analysis
Strengths
- Proprietary nanoviricide technology platform
- Targeted drug delivery system
- Potential for broad-spectrum antiviral activity
- Focused management team
Weaknesses
- Limited financial resources
- Early stage of product development
- High regulatory hurdles
- No currently marketed products
Opportunities
- Growing demand for antiviral therapies
- Potential for partnerships and collaborations
- Expansion into new viral disease targets
- Government funding opportunities
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory delays
- Patent infringement
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GILD
Competitive Landscape
NanoViricides faces significant competition from established pharmaceutical companies with greater resources and marketed products. NanoViricides differentiates itself through its novel nanoviricide technology.
Growth Trajectory and Initiatives
Historical Growth: NanoViricides has not yet achieved significant revenue growth due to its focus on research and development.
Future Projections: Future growth is dependent on the successful development and commercialization of its nanoviricide products. Analyst estimates are highly speculative.
Recent Initiatives: Recent initiatives include advancing clinical trials for its lead nanoviricide candidates and seeking partnerships for further development and commercialization.
Summary
NanoViricides is a high-risk, high-reward biotechnology company focused on developing antiviral therapies. Its proprietary nanoviricide technology offers potential advantages, but the company faces significant financial and regulatory challenges. Success depends on positive clinical trial outcomes and securing funding or partnerships. The lack of current products makes the company susceptible to speculative trading.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Market research reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NanoViricides Inc
Exchange NYSE MKT | Headquaters Shelton, CT, United States | ||
IPO Launch date 2005-10-26 | Executive Chairman, President, CEO & Secretary Dr. Anil R. Diwan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.nanoviricides.com |
Full time employees 7 | Website https://www.nanoviricides.com |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.